Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Next “Surge”: Drug Shortages

This article was originally published in RPM Report

Executive Summary

President Obama’s drug shortage executive order puts drug shortages in some pretty heady company: alongside mortgage relief and jobs for veterans to rescue the economy, and invoking the metaphor of turning points in the Iraq and Afghanistan wars. The order itself won’t change much.

You may also be interested in...



The End of an Era: Lipitor, Blockbuster Drugs and the Waxman/Hatch Model

Pfizer’s Lipitor goes generic—albeit with some decidedly unusual wrinkles. The biggest generic launch in history is a good moment to take stock of the transition away from the blockbuster model. The reaction to the milestone suggests that the industry’s critics may be having a harder time letting go of the old model than industry is.

Early Notification Legislation: What The Bills Say

Both houses have introduced legislation to require manufacturers to notify FDA in advance of planned interruptions or as soon as possible when facing a shortage. Here’s a look at the details.

House ALS Bill Would Require US FDA ‘Action Plan’ – But Not Conditional Approval

US House of Representatives if moving forward with a bill to respond to advocacy from ALS patients for more attention from FDA. The bill focuses on planning and scientific support, not new pathways.

Latest News
See All
UsernamePublicRestriction

Register

PS080906

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel